Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: Utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor

American Journal of Surgical Pathology

Volumn 33, Issue 6, 2009, Pages 914-924

  Yemelyanova, Anna ^a,d   Vang, Russell ^a   Seidman, Jeffrey D ^c   Gravitt, Patti E ^b   Ronnett, Brigitte M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Cervix; Human papillomavirus; Immunohistochemistry

Indexed keywords

HORMONE RECEPTOR; PROTEIN P16; VIRUS DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CARCINOMA IN SITU; CLINICAL ARTICLE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MORPHOLOGY; MYOMETRIUM; NONHUMAN; PROTEIN EXPRESSION; SIMULATION; TUMOR LOCALIZATION; UTERINE CERVIX CARCINOMA; WART VIRUS; ADENOCARCINOMA; BIOSYNTHESIS; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM; ENDOMETRIUM TUMOR; IN SITU HYBRIDIZATION; METABOLISM; MIDDLE AGED; PAPILLOMA VIRUS; PATHOLOGY; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADENOCARCINOMA; ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 67549107973     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181971fdd     Document Type: Article

References (50)

1. Andersson S, Larson B, Hjerpe A, et al. Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet Gynecol Scand. 2003;82:960-965.
2. Andersson S, Rylander E, Larsson B, et al. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer. 2001;37:246-250.
3. Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas: immunohistochem-ical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol. 2004;28:160-167.
4. Cameron RI, Maxwell P, Jenkins D, et al. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology. 2002;41:313-321.
5. Carcangiu ML, Chambers JT, Voynick IM, et al. Immunohisto-chemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am J Clin Pathol. 1990;94:247-254.
6. Chambers JT, Carcangiu ML, Voynick IM, et al. Immunohisto-chemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol. 1990;94:255-260.
7. Czerwenka K, Lu Y, Heuss F, et al. Human papillomavirus detection of endometrioid carcinoma with squamous differentiation of the uterine corpus. Gynecol Oncol. 1996;61:210-214.
8. Dornhofer N, Hockel M. New developments in the surgical therapy of cervical carcinoma. Ann NY Acad Sci. 2008;1138:233-252.
9. Elishaev E, Gilks CB, Miller D, et al. Synchronous and metachro-nous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol. 2005;29:281-294.
10. Ferenczy A, Richart RM, Okagaki T. Endometrial involvement by cervical carcinoma in situ. Am J Obstet Gynecol. 1971;110:590-592.
11. Fujita M, Shroyer KR, Markham NE, et al. Association of human papillomavirus with malignant and premalignant lesions of the uterine endometrium. Hum Pathol. 1995;26:650-658.
12. Fujiwara H, Tortolero-Luna G, Mitchell MF, et al. Adenocarcino-ma of the cervix. Expression and clinical significance of estrogen and progesterone receptors. Cancer. 1997;79:505-512.
13. Giatromanolaki A, Sivridis E, Papazoglou D, et al. Human papillomavirus in endometrial adenocarcinomas: infectious agent or a mere "passenger" ? Infect Dis Obstet Gynecol. 2007;2007:60549.
14. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38:357-361.
15. Grimard L, Genest P, Girard A, et al. Prognostic significance of endometrial extension in carcinoma of the cervix. Gynecol Oncol. 1988;31:301-309.
16. Hording U, Daugaard S, Visfeldt J. Adenocarcinoma of the cervix and adenocarcinoma of the endometrium: distinction with PCR-mediated detection of HPV DNA. APMIS. 1997;105:313-316.
17. Hoskins W, Perez C, Young R, et al. Principles and Practice of Gynecologic Oncology. Philadelphia, PA: Lippincott William & Wilkins; 2005:763-808.
18. Ishikawa M, Fujii T, Masumoto N, et al. Correlation of p16INK4A overexpression with human papillomavirus infection in cervical adenocarcinomas. Int J Gynecol Pathol. 2003;22:378-385.
19. Iwasawa A, Nieminen P, Lehtinen M, et al. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarci-noma detected by polymerase chain reaction. Cancer. 1996;77: 2275-2279.
20. Jones MW, Kounelis S, Papadaki H, et al. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: oncogene/ tumor suppressor gene alterations and human papillomavirus genotyping. Int J Gynecol Pathol. 2000;19:110-117.
21. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284.
22. Kushima M, Fujii H, Murakami K, et al. Simultaneous squamous cell carcinomas of the uterine cervix and upper genital tract: loss of heterozygosity analysis demonstrates clonal neoplasms of cervical origin. Int J Gynecol Pathol. 2001;20:353-358.
23. Luft F, Klaes R, Nees M, et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int J Cancer. 2001;92:9-17.
24. Masood S, Rhatigan RM, Wilkinson EW, et al. Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix. An immunocytochemical study. Cancer. 1993;72:511-518.
25. McCarty KS Jr, Barton TK, Fetter BF, et al. Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. Am J Pathol. 1979;96:171-183.
26. McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarci-noma. Int J Gynecol Pathol. 2003;22:231-235.
27. McCluggage WG, Sumathi VP, McBride HA, et al. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol. 2002;21:11-15.
28. Milde-Langosch K, Riethdorf S, Kraus-Poppinghaus A, et al. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch. 2001;439:55-61.
29. Missaoui N, Hmissa S, Frappart L, et al. p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch. 2006;448:597-603.
30. Murphy N, Heffron CC, King B, et al. p16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Arch. 2004;445:610-615.
31. Mylonas I, Jeschke U, Shabani N, et al. Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR). Anticancer Res. 2005;25:1679-1686.
32. Negri G, Egarter-Vigl E, Kasal A, et al. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocyto-chemical correlations. Am J Surg Pathol. 2003;27:187-193.
33. Noguchi H, Shiozawa I, Kitahara T, et al. Uterine body invasion of carcinoma of the uterine cervix as seen from surgical specimens. Gynecol Oncol. 1988;30:173-182.
34. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol. 2006;13:8-15.
35. Park TW, Zivanovic O, Theuerkauf I, et al. The diagnostic utility of human papillomavirus-testing in combination with immunohisto-chemistry in advanced gynaecologic pelvic tumours: a new diagnostic approach. Int J Oncol. 2004;24:829-836.
36. Perez CA, Camel HM, Askin F, et al. Endometrial extension of carcinoma of the uterine cervix: a prognostic factor that may modify staging. Cancer. 1981;48:170-180.
37. Perez CA, Zivnuska F, Askin F, et al. Prognostic significance of endometrial extension from primary carcinoma of the uterine cervix. Cancer. 1975;35:1493-1504.
38. Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol. 2000;157:1055-1062.
39. Plunkett M, Brestovac B, Thompson J, et al. The value of HPV DNA typing in the distinction between adenocarcinoma of endocervical and endometrial origin. Pathology. 2003;35:397-401.
40. Quizilbash AH, DePetrillo AD. Endometrial and tubal involvement by squamous carcinoma of the cervix. Am J Clin Pathol. 1975; 64:668-671.
41. Ronnett BM, Yemelyanova AV, Vang R, et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol. 2008;32:1835-1853.
42. Semczuk A, Stenzel A, Baranowski W, et al. Detection of human papillomavirus types 16 and 18 in human neoplastic endometrium: lack of correlation with established prognostic factors. Oncol Rep. 2000;7:905-910.
43. Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;106:325-333.
44. Staebler A, Sherman ME, Zaino RJ, et al. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol. 2002;26:998-1006.
45. Tenti P, Romagnoli S, Silini E, et al. Human papillomavirus types 16 and 18 infection in infiltrating adenocarcinoma of the cervix: PCR analysis of 138 cases and correlation with histologic type and grade. Am J Clin Pathol. 1996;106:52-56.
46. Wong WS, Wong YF, Tam OS, et al. Detection of human papilloma virus (HPV) infection in paraffin-embedded tissues of endometrial carcinoma. Aust NZJ Obstet Gynaecol. 1993;33:180-182.
47. Yemelyanova A, Ji H, Ronnett BM. Diffuse p16 expression distinguishes uterine serous carcinoma from uterine endometrioid carcinoma of endometrial origin but not HPV-related endocervical adenocarcinoma. Mod Pathol. 2006;19:202A-203A.
48. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology. 2002;41:185-207.
49. Zaino RJ. The fruits of our labors: distinguishing endometrial from endocervical adenocarcinoma. Int J Gynecol Pathol. 2002;21:1-3.
50. Zielinski GD, Snijders PJ, Rozendaal L, et al. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol. 2003;201:535-543.